Allogene, SpringWorks Collaborate to Test ALLO-715, Nirogacestat Combo for RRMM
Allogene Therapeutics and…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreAllogene Therapeutics and…
Sanofi announced that it partnered with Sebia to develop a…
The U.S. Food and Drug Administration (FDA) has granted priority…
The European Commission has approved Darzalex…
NexImmune will soon initiate a Phase 1/2 trial…
In partnership with Medscape Oncology, the International…